DEF: Carlsmed Sets June 3, 2026 Annual Meeting Date

Carlsmed, Inc. has issued a proxy statement announcing its 2026 Annual Meeting of Stockholders, scheduled for June 3, 2026, to elect directors and ratify auditor appointment.

Summary

• Carlsmed, Inc. is holding its 2026 Annual Meeting of Stockholders on Wednesday, June 3, 2026, at 8:00 a.m. Pacific time, at the offices of Morrison & Foerster LLP in San Diego, CA.
• The meeting agenda includes the election of two Class I directors for three-year terms and the ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
• Stockholders of record as of April 8, 2026, are entitled to vote.
• Proxy materials are being furnished primarily via the internet, with a Notice of Internet Availability of Proxy Materials to be mailed on or about April 22, 2026.
• The company's 2025 Annual Report on Form 10-K is also available.
• Voting can be done via the internet, telephone, mail (if paper copies requested), or in person at the meeting.
• The Board of Directors unanimously recommends voting FOR the election of the nominated directors and FOR the ratification of Ernst & Young LLP.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it indicates the company is proceeding with standard governance procedures and has a well-structured board and committees, but it contains no new financial or strategic performance information.

Positives

• The company is holding its annual meeting as scheduled, indicating ongoing operational and governance processes.
• The use of internet-based proxy material distribution is noted as more efficient, less costly, and environmentally friendly.
• A majority of the board members (five out of seven) are independent, aligning with good corporate governance standards.
• The company has established clear corporate governance guidelines, a code of conduct, and policies for director independence and risk oversight.
• The audit committee is composed of independent members, with one member (Kevin O'Boyle) identified as an audit committee financial expert.
• The company has adopted a clawback policy and an insider trading policy to further strengthen governance and compliance.
• Director compensation is structured with annual retainers and equity awards (RSUs) designed to attract and retain qualified individuals.
• The company has a robust process for nominating directors, considering individual qualifications, existing commitments, and board composition.

Negatives

• The filing does not contain financial performance data, as it is a proxy statement for an upcoming meeting.
• The company is an 'emerging growth company,' which allows for reduced public company reporting requirements, potentially limiting disclosure in certain areas like executive compensation.

Risks

• The election of directors is determined by a plurality of votes cast, meaning withheld votes and broker non-votes will have no effect on the outcome.
• While not explicitly stated as a risk, the reliance on proxy voting via internet or telephone means that any technical issues or lack of stockholder engagement could impact the quorum or voting outcomes.
• The company's policy on related person transactions requires review and approval by the audit committee, but the potential for conflicts of interest, even if perceived, remains a consideration.

Future Outlook

The filing is a proxy statement for an upcoming annual meeting and does not contain specific forward-looking financial guidance. It outlines the proposals to be voted on, including the election of directors and ratification of the auditor for the fiscal year ending December 31, 2026.

Management Comments

• "Your vote is important. Please cast your vote as soon as possible over the internet, by telephone, or by completing and returning a proxy or voting instruction card to ensure that your shares are represented."
• "We believe the use of the internet makes the proxy distribution process more efficient and less costly and helps in conserving natural resources."
• "On behalf of our board of directors and our employees, we thank you for your continued interest in and support of our company."
• "We believe that Mr. Casey is qualified to serve on our Board of Directors due to his experience as our Chief Intellectual Property Officer and Co-Founder and due to his leadership, education, professional credentials, and significant experience in the spine industry."
• "We believe that Mr. Young is qualified to serve on our Board of Directors due to his experience serving as a director on boards of both public and private companies."
• "We believe that Mr. Cordonnier is qualified to serve on our Board of Directors as the Chairman due to his experience as our Chief Executive Officer, President, and Co-Founder and due to his leadership and business acumen."
• "We believe that Dr. Mittendorff is qualified to serve on our Board of Directors due to his experience serving as a director on the boards of both public and private companies."
• "We believe that Mr. OBoyle is qualified to serve on our Board of Directors due to his experience serving as a director on boards of other companies in the medical device industry, financial expertise, and extensive management experience in the medical device industry."
• "We believe that Dr. Root is qualified to serve on our Board of Directors due to his experience serving on the boards of both public and private companies."
• "We believe that Mr. Sidow is qualified to serve on our Board of Directors due to his experience serving as a director on the boards of private companies and his extensive experience in the medical device industry."

Industry Context

StockSavvy.ai notes that this filing is typical for a publicly traded company preparing for its annual shareholder meeting. The focus on director elections, auditor ratification, and corporate governance practices reflects standard procedures for maintaining compliance and shareholder engagement in the medical technology sector.

Comparison to Industry Standards

• The board composition, with five out of seven directors being independent, aligns with or exceeds the independence requirements set by major exchanges like Nasdaq for companies in the medical technology sector.
• The establishment of independent audit, compensation, and nominating/corporate governance committees is a standard best practice for publicly traded companies, including those in the medical device and life sciences industries.
• The director compensation structure, including annual retainers and equity awards, is comparable to industry norms for companies of similar size and stage, aiming to attract experienced professionals.
• The company's commitment to strong corporate governance, including a code of conduct and detailed guidelines, is consistent with evolving expectations for transparency and accountability in the healthcare and technology sectors.

Corporate Governance

Legal Proceedings

• No current or past directors or executive officers have been involved in criminal convictions or bankruptcy filings within the past ten years, with one exception noted for Scott Durall's prior executive role.
• No current or past directors or executive officers have been subject to significant legal judgments or orders related to securities law violations or financial misconduct within the past ten years.

Related Party Transactions

• In January 2025, Carlsmed completed a Series C convertible preferred stock financing, with entities affiliated with B Capital Group and U.S. Venture Partners purchasing significant amounts.
• Directors Robert Mittendorff (affiliated with B Capital Group) and Jonathan D. Root and Philip Young (affiliated with U.S. Venture Partners) have interests in these related party transactions.
• Entities affiliated with B Capital Group and U.S. Venture Partners also purchased $20.0 million and $11.0 million, respectively, in shares of common stock in the company's IPO.

Stakeholder Impact

• Shareholders: The meeting provides an opportunity for shareholders to vote on director elections and auditor ratification, influencing corporate governance and oversight.
• Management and Employees: Executive compensation is detailed, with base salaries, incentive plans, and equity awards designed to align interests. Employment agreements outline severance and change-in-control benefits.
• Auditors: The ratification of Ernst & Young LLP as the independent auditor impacts the company's financial reporting and audit process.
• Board of Directors: The election of directors and the structure of board committees and compensation are detailed, affecting the board's oversight and decision-making capabilities.

Next Steps

• Stockholders are encouraged to vote their shares by June 2, 2026.
• The 2026 Annual Meeting of Stockholders will be held on June 3, 2026.
• Final voting results will be published in a Form 8-K filing within four business days after the Annual Meeting.

Key Dates

Recommendation

This filing is a routine proxy statement for an annual meeting and does not contain new financial performance data, strategic updates, or significant operational news that would warrant a buy or sell recommendation. It outlines standard governance procedures and upcoming voting items. Therefore, a 'hold' recommendation is appropriate, pending future performance-related disclosures.

Keywords

Carlsmed, Proxy Statement, Annual Meeting, DEF 14A, Stockholders, Board of Directors, Director Election, Auditor Ratification, Ernst & Young, Corporate Governance, SEC Filings